This study found that Botox® was most effective at a 25 U/ml concentration, while Dysport® and Neurobloc® were optimal at 100 U/ml for producing anhidrotic areas after injections.
December 2024 in “PubMed”
July 2023 in “Skin health and disease” This study surveyed UK patients who experienced adverse events from Botulinum Toxin for cosmetic purposes, finding 79% reported issues like long-lasting anxiety, and highlighting low awareness of regulatory bodies and reporting structures.
8 citations
,
March 2020 in “Pain Medicine” This case report describes a woman with refractory trichodynia who became asymptomatic after receiving botulinum toxin type A injections, suggesting potential efficacy of this treatment for persistent trichodynia.
53 citations
,
January 2017 in “Skin appendage disorders” This review discusses botulinum toxin's experimental off-label uses in dermatology, highlighting promising results but emphasizing the need for more clinical trials to confirm efficacy and safety.